Literature DB >> 21427503

Severe thyroid-associated orbitopathy in Hashimoto's thyroiditis. Report of 2 cases.

Ai Yoshihara1, Jaeduk Yoshimura Noh, Ayako Nakachi, Hidemi Ohye, Shiori Sato, Kenichi Sekiya, Yuka Kosuga, Miho Suzuki, Masako Matsumoto, Yo Kunii, Natsuko Watanabe, Koji Mukasa, Yoichi Inoue, Kunihiko Ito, Koichi Ito.   

Abstract

Thyroid-associated orbitopathy (TAO) is characterized by immune-mediated inflammation of the extraocular muscles surrounding orbital connective tissue and adipose tissue. Severe orbitopathy related to autoimmune thyroid disease often occurs in patients with Grave's disease, but it is rare in patients with Hashimoto's thyroiditis. The pathogenesis of TAO is unclear. Several studies have noted a strong correlation between the levels of antibodies to thyrotropin receptor antibody (TRAb) and TAO in Graves' disease. Mild upper eyelid retraction has been reported to be common in Hashimoto's thyroiditis patients, however severe orbitopathy is rare. We report two cases of severe TAO in patients with Hashimoto's thyroiditis who required systemic glucocorticoid therapy and orbital irradiation to treat the TAO. The activity of the TAO was high in both patients, because their clinical activity scores (CAS) for the orbitopathy were high, and magnetic resonance imaging (MRI) showed enlargement of the extraocular muscles and an increase in T2 signal intensity and prolonged T2 relaxation time which indicate an active stage of inflammation. We tested the presence of TRAb by three different assays and were negative in both patients. Since the eye muscle damage cannot be due to TSH receptor antibodies, other pathogenetic mechanisms may be responsible for the orbitopathy in patients with Hashimoto's thyroiditis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427503     DOI: 10.1507/endocrj.k11e-019

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  8 in total

1.  Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease.

Authors:  Terry J Smith; Dolly A Padovani-Claudio; Ying Lu; Nupur Raychaudhuri; Roshini Fernando; Stephen Atkins; Erin F Gillespie; Andrew G Gianoukakis; Barbra S Miller; Paul G Gauger; Gerard M Doherty; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  Hashimoto's thyroiditis associated with acute painful unilateral ophthalmoplegia.

Authors:  Byungseok Kim; Taewon Kim
Journal:  Neurol Sci       Date:  2019-08-05       Impact factor: 3.307

3.  Presence of thyroid-associated ophthalmopathy in Hashimoto's thyroiditis.

Authors:  Emrah Kan; Elif Kilic Kan; Gülcin Ecemis; Ramis Colak
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

Review 4.  Diplopia in a patient with Hashimoto's thyroiditis: A case report and literature review.

Authors:  Chengqun Ju; Linna Zhang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Not All Orbitopathy Is Graves': Discussion of Cases and Review of Literature.

Authors:  Neeraja Boddu; Maliha Jumani; Vibhor Wadhwa; Gitanjali Bajaj; Fred Faas
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

Review 6.  Non-Conventional Clinical Uses of TSH Receptor Antibodies: The Case of Chronic Autoimmune Thyroiditis.

Authors:  Giorgio Napolitano; Ines Bucci; Giulia Di Dalmazi; Cesidio Giuliani
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-05       Impact factor: 5.555

Review 7.  Epidemiology of Ocular Manifestations in Autoimmune Disease.

Authors:  Katie Glover; Deepakkumar Mishra; Thakur Raghu Raj Singh
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

8.  Imaging of the medial rectus muscle predicts the development of optic neuropathy in thyroid eye disease.

Authors:  Marcel Berger; Juliane Matlach; Susanne Pitz; Manfred Berres; Franz Axmacher; George J Kahaly; Marc A Brockmann; Matthias Müller-Eschner
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.